{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DCV&page=2", "query": { "intervention": "DCV", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DCV&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-11T09:46:38.249Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01471574", "title": "Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C, Genotype 1" ], "interventions": [ { "name": "Daclatasvir", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "PEG-Interferon alfa 2a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 549, "start_date": "2011-12", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2016-01-29", "last_synced_at": "2026-09-11T09:46:38.249Z", "location_count": 23, "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01471574" }, { "nct_id": "NCT02098616", "title": "Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "DCV/ASV/BMS-791325", "type": "DRUG" }, { "name": "DCV/ASV/BMS-791325 + RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Timothy Morgan, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2014-07", "completion_date": "2016-02", "has_results": false, "last_update_posted_date": "2016-04-19", "last_synced_at": "2026-09-11T09:46:38.249Z", "location_count": 1, "location_summary": "Long Beach, California", "locations": [ { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02098616" }, { "nct_id": "NCT00663208", "title": "A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C" ], "interventions": [ { "name": "Daclatasvir", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 167, "start_date": "2008-05", "completion_date": "2009-06", "has_results": true, "last_update_posted_date": "2015-10-14", "last_synced_at": "2026-09-11T09:46:38.249Z", "location_count": 7, "location_summary": "Anaheim, California • Cypress, California • New Haven, Connecticut + 4 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Cypress", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00663208" }, { "nct_id": "NCT01718158", "title": "Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Peginterferon Lambda-1a", "type": "BIOLOGICAL" }, { "name": "Peginterferon Alfa-2a", "type": "BIOLOGICAL" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Daclatasvir", "type": "DRUG" }, { "name": "Telaprevir", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 444, "start_date": "2013-01", "completion_date": "2014-10", "has_results": false, "last_update_posted_date": "2015-10-09", "last_synced_at": "2026-09-11T09:46:38.249Z", "location_count": 8, "location_summary": "Long Beach, California • Marietta, Georgia • New York, New York + 5 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Marietta", "state": "Georgia" }, { "city": "New York", "state": "New York" }, { "city": "Poughkeepsie", "state": "New York" }, { "city": "Allentown", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01718158" }, { "nct_id": "NCT01125189", "title": "Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C Virus" ], "interventions": [ { "name": "Daclatasvir", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "peg-interferon alfa-2a", "type": "DRUG" }, { "name": "ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 558, "start_date": "2010-07", "completion_date": "2012-08", "has_results": true, "last_update_posted_date": "2015-10-23", "last_synced_at": "2026-09-11T09:46:38.249Z", "location_count": 33, "location_summary": "Montgomery, Alabama • La Jolla, California • Los Angeles, California + 26 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01125189" }, { "nct_id": "NCT01741545", "title": "Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C Virus" ], "interventions": [ { "name": "Pegylated-Interferon-lambda", "type": "BIOLOGICAL" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Daclatasvir", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 71, "start_date": "2013-03-31", "completion_date": "2015-01-31", "has_results": true, "last_update_posted_date": "2020-08-11", "last_synced_at": "2026-09-11T09:46:38.249Z", "location_count": 4, "location_summary": "Palo Alto, California • Chicago, Illinois • Philadelphia, Pennsylvania + 1 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Murray", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01741545" }, { "nct_id": "NCT00859053", "title": "Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic Impairment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatic Insufficiency" ], "interventions": [ { "name": "BMS-790052", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 46, "start_date": "2009-03", "completion_date": "2009-09", "has_results": true, "last_update_posted_date": "2015-10-08", "last_synced_at": "2026-09-11T09:46:38.249Z", "location_count": 2, "location_summary": "Anaheim, California • Orlando, Florida", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00859053" }, { "nct_id": "NCT02032901", "title": "Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Daclatasvir", "type": "DRUG" }, { "name": "Sofosbuvir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 173, "start_date": "2014-01", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2015-10-01", "last_synced_at": "2026-09-11T09:46:38.249Z", "location_count": 30, "location_summary": "La Jolla, California • Los Angeles, California • Pasadena, California + 23 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02032901" }, { "nct_id": "NCT01573351", "title": "Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C Virus" ], "interventions": [ { "name": "Asunaprevir", "type": "DRUG" }, { "name": "Daclatasvir", "type": "DRUG" }, { "name": "Peg-interferon Alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 398, "start_date": "2012-05", "completion_date": "2013-12", "has_results": false, "last_update_posted_date": "2015-10-09", "last_synced_at": "2026-09-11T09:46:38.249Z", "location_count": 20, "location_summary": "Montgomery, Alabama • La Jolla, California • Los Angeles, California + 16 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Englewood", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01573351" }, { "nct_id": "NCT02709993", "title": "Consolidation Therapy in Patients With Hematologic Malignancies", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cancer", "Hematologic Malignancies" ], "interventions": [ { "name": "TAPA-pulsed DC vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Kiromic BioPharma Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2017-07-28", "completion_date": "2020-10-31", "has_results": false, "last_update_posted_date": "2019-10-14", "last_synced_at": "2026-09-11T09:46:38.249Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02709993" } ] }